SCHEMBL4774175

SCHEMBL4774175

COc1cc(OC)c(-c2cc3ccccc3c(=O)[nH]2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.52
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GAA P10253 2/20 0.49
CDC25B P30305 2/20 0.48
APAF1 O14727 1/20 0.48
TDP2 O95551 1/20 0.48
CASP3 P42574 1/20 0.48
CASP7 P55210 1/20 0.48
CASP9 P55211 1/20 0.48
CASP6 P55212 1/20 0.48
CASP8 Q14790 1/20 0.48
SENP8 Q96LD8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763653 0.90 KDM4E (0.63) THRBKDM4EALDH1A1HPGDRAB9A
SCHEMBL4771998 0.87 CDC25B (0.57) THRBKDM4EALDH1A1HPGDRAB9A
SCHEMBL4774288 0.85 CDC25B (0.60) THRBKDM4EALDH1A1HPGDRAB9A
SCHEMBL4773592 0.82 THRB (0.52) THRBKDM4EALDH1A1HPGDRAB9A
SCHEMBL4766308 0.81 GUSB (0.60) THRBKDM4EALDH1A1HPGDMAPT
SCHEMBL4766918 0.75 TNKS (0.47) THRBKDM4EMAPTNPSR1CDC25B
SCHEMBL13316854 0.75 KDM4E (0.59) THRBKDM4EALDH1A1HPGDRAB9A
SCHEMBL4771349 0.75 TNKS (0.54) THRBKDM4EALDH1A1HPGDRAB9A
SCHEMBL4769021 0.75 TNKS (0.64) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL509972 0.74 KDM4E (0.57) THRBKDM4EALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 THRB 1793/4885KDM4E 1058/4885ALDH1A1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.